VGI Health Technology : June 2022 Quarterly Update

VGI Health Technology Limited

ABN: 35 111 082 485

Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000

www.vgiht.com | Tel: [phone]

VGI Health Technology Limited - June 2022 Quarterly

Update

Sydney, New South Wales, 29 July 2022 - The Directors of VGI Health Technology Limited (the Company or VTL) are pleased to provide the following update for the quarter ending 30 June 2022.

Status of Patent Ownership

On 4 April 2022, VGI Health Technology Limited was pleased to announce that the the United States Patent and Trademarks Office (USPTO) intends to grant a divisional patent for the 'Transmucosal Delivery of Tocotrienols' to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd. Previously, a US patent directed to a method of treating post exercise muscle soreness or delayed onset muscle soreness (DOMS) by transmucosal administration of a tocotrienol was granted in June 2020. The present divisional patent application extends this coverage to pharmaceutical compositions containing delta tocotrienol which have been formulated for transmucosal delivery. This composition can be used for the treatment or prevention of additional indications such as fibrosis and cancer. Once granted, the patent formally entitled 'Transmucosal Delivery of Tocotrienol' will provide commercial rights in the US until 13 November 2032.

Technological and Product Development

On 21 March 2022, VGI Health Technology Limited (NSX:VTL) was pleased to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, will be presenting an abstract at the American Society for Nutrition (ASN) Annual Conference, Nutrition 2022. In association with the ASN, an abstract will be presented during the conference (14-16 June 2022) titled "Transmucosal delivery of tocotrienols from a delta-tocotrienolpowder: A Multidose Pharmacokinetic study". The abstract describes some of the results that have been generated from a pharmacokinetics study conducted by Dr Moon in the US using new formulations developed for the transmucosal delivery of tocotrienols. These new formulations and methods of manufacture are also the subject of a new patent filing "PCT/AU2021/051449 - Transmucosal delivery of tocotrienols" made by VTL's wholly- owned subsidiary Invictus Biotechnology Pty Ltd on 3 December 2021. The data from this study supports the fact that there is more flexibility with dosages for this particular drug delivery platform than earlier research data had suggested.

Sixteen healthy research subjects (m=8, f=8, 32 +/- 8 years, 171 +/- 7 cm, 81.6 +/- 13.8 kg) were randomly administered either 40mg or 80mg of a delta tocotrienol (DT3) containing powder in a fasted state. Subjects were asked to keep the powder under their tongue until it was fully dissolved. Blood samples were taken at 0, 60, 90, 120, 180, 240, 360, and 480 minutes. Subjects were given a meal consisting of carbohydrates, proteins, and fats after four hours. DT3 concentrations were calculated from blood plasma using protein precipitation followed by liquid-liquid extraction. Analytes were separated by Liquid Chromatography Mass Spectrometry (LCMS) with the extracts assayed against a calibration curve. DT3 bioavailability was assessed using the parameters peak plasma concentration (Cmax), time to reach peak plasma concentration (Tmax) and total area under the plasma concentration-time curve (AUC).

1

VGI Health Technology Limited

The plasma concentration of DT3 reached 44.05 ng/ml (Cmax) for the 40mg group and reached

127.4 ng/ml (Cmax) (+83.4 ng/ml increase) for the 80mg group. Tmax was achieved at 360 minutes for both the 40 and 80mg group. AUC for 40mg resulted in 9,941.6 ng/ml*min, with a +2.9 times increase observed in the 80mg group (29,072.2 ng/ml*min) compared to 40mg.

Transmucosal delivery of tocotrienols from a delta-tocotrienol powder containing 40mg and 80mg of DT3 resulted in a progressively elevated absorption rate for both doses with 80mg appearing to increase total plasma DT3 by a difference of +2.9 times that of a 40mg dose. Both 40 and 80mg doses of DT3 administered via transmucosal delivery have shown enhanced plasma DT3 concentrations in healthy men and women over a period of no less than 8 hours.

Customer Recruitment

There were no new developments in relation to customer recruitment for this quarter.

Quarterly Revenue

An update on the revenue for the June quarter will be provided in the NSX quarterly update to be released to the Market before the end of July.

Staff Recruitment

No new staff were recruited during the quarter.

For more information please contact:
Dr Glenn Tong, CEO and Managing Director	Mrs Catriona Glover, Company Secretary
Ph: [phone]	Tel: [phone]

2

VGI Health Technology Limited

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence- based nutraceuticals.

For more information see: https://www.vgiht.com

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp

3